îæ€çŽ¢
îæ€çŽ¢
î
Abivax SA
ABVXîãŠã©ãããªã¹ãã«è¿œå
124.810USD
+0.480+0.39%
çµå€Â 07-31 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
0.00æ䟡ç·é¡
--çŽè¿12ã¶æPER
詳现æ å ± Abivax SA äŒæ¥å
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SAã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãABVX
äŒç€ŸåAbivax SA
äžå Žæ¥Jun 26, 2015
æé«çµå¶è²¬ä»»è
ãCEOãde Garidel (Marc)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Depository Receipt
決ç®ææ«- -
æ¬ç€Ÿæåšå°7-11 Boulevard Haussmann
éœåžPARIS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœFrance
éµäŸ¿çªå·75009
é»è©±çªå·33153830963
ãŠã§ããµã€ãhttps://www.abivax.com/
äŒæ¥ã³ãŒãABVX
äžå Žæ¥Jun 26, 2015
æé«çµå¶è²¬ä»»è
ãCEOãde Garidel (Marc)
Abivax SAã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
ãããã質å
Abivax SAã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îAbivax SAã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ããMr. Pierre Courteille
Abivax SAïŒABVXïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2026Q1æç¹ã§ãAbivax SAã®æ ªåŒãä¿æããŠããæ©é¢ã¯353瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ61.40Mã§ãå
šäœã®78.18%ãå ããŠããŸãã2025Q4ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-289711.00å¢å ããŠããŸãã